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TREATMENT of acute myeloid leukaemia (AML) cells with
differentiation agents leads not only to the acquisition of
normal phenotypes but also contributes to the under-
standing of special immuno-haematology issues. For
instance, induction of HLA-DR antigens on human
promyelocytic leukaemia HL-60 cells by interleukin-4 (IL-
4) is of pivotal importance in immunology not only be-
cause class II expression is prerequisite to antigen recog-
nition and response but also because IL-4 participates in
a plethora of inflammatory or non-inflammatory reac-
tions. At the same time, the same observation coupled
with an increase in Mac-l, mature monocyte marker, is
revealing ways to haematologists for converting malig-
nant cases to normal situations. Based on previous re-
ports that HLA-DR induction by IL-4 in the HL-60 system
is mediated via the G-protein system (p21r’s), this study
was undertaken in order to define the intermediate sig-
nalling steps followed by this agent from the moment it
is added to cultures to the differentiated cellular form
obtained. It is proposed that IL-4 increases p21 which
in turn suppresses the HL-60 cells’ p34cdc2 constitutive
expression. This inhibition appears to be responsible for
the subsequently.observed cessation ofgrowth. Concomi-
tant to decreased cellular proliferation, HI-DR antigen
expression increases, a finding that matches the initially
mentioned induction of p21 since its inhibition abol-
ishes HI-DR upregulation.
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Introduction
IL-4 is a T-cell derived factor1," exerting its biologi-
cal actions mainly on B-cells. However, the presence
of the IL-4 receptor is not restricted to the B-cell
lineage but also found on a variety of other cells and
cell lines, one of which is the human promyelocytic
leukaemia HL-60 cell line. This line was derived
from an acute myeloid leukaemia (AML) patient with
cells arrested at the blast stage. Terminal differentia-
tion of HL-60 cells can be achieved by external
stimuli like chemical components or biological
agents (for review see Collins6). The obvious advan-
tage of physiological agents vis-t-vis chemicals led
this investigation to the use of IL-4 since this line
expresses IL-4 receptors ectopically.4,7 It has been
previously shown that IL-4 is able to initiate a matu-
ration programme and lead the immature, class II
negative HL-60 cells to a differentiated state express-
ing HLA-DR surface antigens. These antigenic deter-
minants were shown to be mediated via the G-
protein system since p21 induction was shown to
be concomitant to class II after IL-4 administration.
More recent reports in the Xenopus system claimed
that oncogenic ras may block cell cycle progression
( 1994 Rapid Communications of Oxford Ltd
and inhibit p34cc" kinase activity by a mechanism
other than blocking cyclin B synthesis or formation
of the cyclin B-p34c" complex, both absolutely
necessary for a cell to progress through mitosis, m-le
Since HL-60 has a high and abnormal proliferative
rate, one may hypothesize that this unlimited growth
behaviour is due to the presence of the cdc2 gene
product, p34, as it happens to other similar cells and
cell lines.3 Once this question was answered posi-
tively (this work) and in conjunction with the ability
IL-4 has to induce p21 in the same system, an effort
was made to put the pieces of the puzzle together
and follow all the possible intracellular signals from
the moment IL-4 comes in contact with the cells up
to the differentiated state.
It is proposed that the possible cascade of events
taking place after IL-4 administration are an increase
of p21 which suppresses the constitutive expres-
sion of p34coce thus leading to a controlled cellular
growth pattern and an increase in class II expression.
Since inhibition of induced p21 brings p34 and
HLA-DR expressions to control levels, it is likely that
the proposed sequence represents the actual situa-
tion.
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Materials and Methods
Cells: HL-60 cells5,6 were purchased from the Ameri-
can Type Culture Collection (ATCC, Rockville, MD)
and were grown in RPMI 1640 culture medium
(Gibco, Grand Island, NY) supplemented with 10%
foetal calf serum (FCS, Seralab, Sussex, UK) at 37C,
5% CO2.
Growthfactors and antibodies: Human recombinant
IL-4 was purchased from Genzyme (Boston, MA) and
was used at a concentration of 200 units/ml (200 U
of IL-4 contain 0.01 lttg of protein). The anti-p21
monoclonal antibody, a rat IgG, was purchased from
Oncogene Science (Manhasset, NY) and used at a
dilution of 1:100 (1.01.tg). The IgG1 anti-cdc2
monoclonal antibody was purchased from UBI
(Lake Placid, NY) and used at a concentration of
10 t.tg/ml (1 t.tg test). Viability tests by Trypan blue
dye exclusion were used to demonstrate that all
working solutions were not toxic.
Induction protocol: One hundred thousand HL-60
cells were cultured with 200 U/ml IL-4 on Day 0. At
24 and 48 h, another boost of the same dose of
IL-4 was administered to cells and class II as well as
p34
cc2 surface expression was monitored at 72 h.
HLA-DR analysis: HLA-DR was monitored with the
use of Dynabeads (Dynal A.S., Norway) coated with
a human anti class II (DR) monoclonal antibody in
one-step experiments as previously described. The
number of cells and beads employed was in accord-
ance with the manufacturer’s instructions.
Indirect immunofluorescence for determining ras
and p34
cc2 expression: Control and treated HL-60
cells were washed in PBS (Gibco) and placed in 96-
well plates (Linbro, Flow Labs, McLean, VA) at a
concentration of 5 x 106 cells/ml. The cells were
incubated with PBS supplemented with 0.2% BSA
(Sigma, St Louis, MO) and 0.01% sodium azide
(Sigma, PBS-BSA-Azide). Before testing, the cells
were incubated with 20% ice-cold methanol for
15 min to allow membrane permeabilization since
the ras antigen is found in the inner surface mem-
brane of the cells. 14 For p34
cc2 detection, the ice-cold
methanol treatment was omitted. Test antibodies,
diluted as described above, were added to the wells
(100 t.d/well) and incubated for 45 min at 4C. After
washing the cells three times with PBS-BSA-Azide,
FITC-conjugated goat-anti-rat or anti-mouse respec-
tively IgG antibody (Tago Inc., Burlingame, CA) was
added for 45 min at 4C. The cells were extensively
washed, fixed with 25% glycerol, and mounted on
slides. Fluorescence was evaluated visually using a
Zeiss (Oberkochen, Germany) fluorescent micro-
scope. Cells with weak or no staining were scored as
negative. Positive cells were considered to be those
showing bright to very bright staining.
3H-TdR incorporation assay. HL-60 cells were
cultured at a concentration of 5x103 cell/ml in 96-
well plates (V-bottom) with or without IL-4. Cultures
were assessed for 3H-thymidine (H-TdR) nuclear
incorporation after 3 days of incubation. One l.tCi of
H-TdR (of 20 Ci/mmol specific activity; NEN, Boston,
MA) was added per well 4 h prior to harvest and
then the cells were placed in scintillation fluid
(toluen-omnifluor, NEN, 1.38 g/l) and counted in
a beta counter (LKB, Finland).
Statistical analysis: In all experiments that were per-
formed at least three times in triplicate, the Student’s
t-test was used for the evaluation of significance
levels (p). All other statistical values show the mean
+ standard deviation (SD).
Results
p34 as a candidate moleculefor excessive cellgrowth:
The rapid proliferative potential of the human
promyelocytic leukaemia cell line HL-605,6 has not so
far been explained. Although many hypotheses have
been formulated concerning soluble factors elabo-
rated in its culture medium<15 no conclusive answer
has yet been offered. It has been suggested, how-
ever, that a large panel of cells and cell lines, some
of which are related to the HL-60 system in terms of
lineage restriction, owe their uncontrolled growth to
the product of the cdc2 gene, p34.1 It was obvious
then to inquire whether HL-60 also expressed such
a product. By immunocytometric analysis it was
shown that indeed the cells expressed constitutively
almost 50% of surface p34
cc2 (Table 1), a protein that
is found on the cell’s membrane as well as
intracellularly.1 In marked contrast, normal human
monocytes, already differentiated and with no left
capacity to proliferate without exogenous aid,
showed no levels of p34cc" expression whatsoever
(Table 1). The conclusion from these two situations
was that the anomalous growth of HL-60 could be
caused by the p34 presence.
Table 1. Constitutive p34cc2 expression on human leukaemia cells
may indicate a role for the cdc2 kinase in cellular growth
Cell type Percentage of positive cells (+ SD)
as assessed by immunofluorescence*
p34CC2
HL-60 49 + 3**
KG-la 28 + 2**
Normal monocytes 2 +
*As described in the Materials and Methods.
**Statistically significant compared with control value (normal
monocytes).
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IL-4 as the link between p21 and p34cdc2: Differen-
tiation of HL-60 cells can be achieved after an appro-
priate chemical or physiological treatment. 6,8 For
instance and for the sake of this work, IL-4 may drive
these immature cells to express HLA-DR surface an-
tigens, a marker of maturation. Such induction has
been shown by this laboratory to be G-protein
(p21ras)-dependent.8 In addition, Pan et al. have
reported that in the Xenopus system oncogenic ras
can block cell cycle progression by inhibiting p34
cdc2
activity. Therefore, since in our system induction of
p21 could be achieved by IL-4 treatment, the hy-
pothesis formulated was that upregulation of this
gene could be responsible for the differentiation IL-
4 induced events via p34 modulation. The goal was
to analyse the possible signals IL-4 could transmit to
the HL-60 cells as to obtain a more mature progeny.
As Table 2 shows, IL-4 indeed increases ras levels
significantly (p < 0.001) and at the same time inhibits
constitutive p34 expression (p< 0.001).
Following the pathway. In order to establish which
event was first, co-culture of HL-60 cells with IL-4 and
anti-p21 ras, a known inhibitor of ras, was performed.
It was shown that this combination could abolish the
ras induction and restore the p34 expression, indicat-
ing that induction of ras precedes p34 modulation.
According to the results of p34 on normal monocytes
as described earlier, one could expect that
downregulation of p34
cdc2 would bring cessation of
cellular growth. Tritiated-thymidine incorporation
assays demonstrated that this was exactly the case
(Table 3). IL-4 could interfere at the abnormal prolif-
eration rate of the cells by decreasing it significantly
(p< 0.05). At the same time, HL-60 cells could be
induced to express class II surface antigens as previ-
ously described. To support the original conclusion
that ras comes first as a signal transduced, it had to
be demonstrated that inhibition of induced-ras (by
the combination of IL-4 + anti-p21 monoclonal
Table 2. IL-4 induces p21 and at the same time downregulates
p34:e:2
Treatment Percentage of positive cells*
(+ SD); day 3
p21 p34CeC2
None 5 + 50 + 3
IL-4** 24 + 4*** 25 + 2***
anti-p21 + 48 +/- 5
IL-4 + anti-p21 11 +/- 4 53 +/- 4
*By immunofluorescence as given in the Materials and Methods.
**Doses and detailed experimental protocols are given in the Ma-
terials and Methods. Note that all assays were performed on
day 3 (72 h) of culture, a timing that was best for class II induction.
***Statistically significant compared with control value (no treat-
ment), p values are given in the text.
Statistically significant compared with inducer value (IL-4). p
values are given in the text.
Table 3. Cessation of growth is associated with HLA-DR
upregulation
Treatment Percentage of positive cells* aH-TdR*
(+/- SD); day 3 (cpm +/- SD); day 3
HLA-DR Proliferation
None 6 +/- 2 3020 +/- 224
IL-4 42 +/- 6** 987 +/- 89**
anti-p21 9 +/- 2895 +/- 138
IL-4 + anti-p21 11 +/- 2*** ND
*lmmunofluorescence and proliferation protocols are given in the
Materials and Methods.
**Statistically significant (p < 0.001) compared with control value
(no treatment).
***Blockade of DR induction by anti-p21 antibody shows the
sequence of events as described in the Results and Discussion
sections.
antibody) could, except for restoring the suppressed
p34 expression, inhibit the IL-4-induced HLA-DR
upregulation. Indeed, blocking induction of ras
reverted the cells to their initial class II negative
phenotype.
Discussion
IL-4 is an immunoregulatory lymphokine with
multiple properties on immunological and
haematological issues. Although it was first described
as a co-factor for B-cell proliferation, it was later
shown to bind receptors on B- and T-lymphocytes,
mast cells, macrophage, 16 and other types of cells.
Among its properties, one can briefly mention its role
on (1) the regulation of B-cell growth, development
and expression of membrane antigens; (2) its ability
as a switch factor for IgE and IgG1 in vitro and
in vivo; and (3) the regulation of T-cell growth and
T-cell development in the thymus (for review see
Pau117). In addition, one must not neglect its actions
on a variety of haematopoietic cells, antitumour
properties and proinflammatory involvement.
17q9
Recently, it has been shown that IL-4 may modulate
gene expression for a number of colony-stimulating
factors (CSFs) and interleukins like IL-1 and IL-6.19
Considering the above outlined properties, it has
to be taken into account that the role of IL-4 is
important for the initiation, maintenance and final
yield of many regulatory mechanisms. Having the
knowledge that IL-4 induces differentiation and class
II antigen expression on HL-60 cells,18 and that the
p21 pathway is being activated by its presence in
relation to class II upregulation, this study was un-
dertaken in order to follow the possible intermediate
pathways from the moment of IL-4 administration
and until an autonomously grown cell, due to p34
expression, reaches a differentiated state.
The results presented in this study, not only sup-
port the hypothesis of Pan et al.9 that ras may block
cell cycle progression by p34 inhibition, but also
Mediators of Inflammation. Vo13. 1994 417S. Vassiliadis
point to the sequence of signals transduced by IL-4
on the HL-60 leukaemic population. It can be con-
cluded that once IL-4 is added to the cells, an initial
induction of ras is the major event responsible for the
cascade that follows until the differentiation of this
malignant clone. The IL-4 induced, ras-dependent
inhibition of p34 appears to be responsible for the
growth arrest, a very important step in the study of
malignancy in general. Such inhibition brings an
elevation of the maturation marker HLA-DR which
shows that the cells have been programmed to dif-
ferentiate and acquire a normal phenotype through
this network of interactions that are reported for the
first time for this particular factor and cells.
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